Drugs that target advanced ... as an option for patients with HER2‑positive locally advanced or metastatic breast cancer who ...

which is also comparing the drug to standard treatment for advanced NSCLC with activating HER2 mutations. At the moment, there is only one oral anti-HER2 drug on the market, Pfizer's Tukysa ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

It's a spectacular result in a patient population with few effective treatment options and the first clear evidence that anti-HER2 therapy can ... at pushing use of the drug into earlier lines ...

26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation ...